Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: March 10, 2008
Last updated: January 10, 2011
Last verified: January 2011
To evaluate the single-dose and steady-state pharmacokinetics of desloratadine and fexofenadine in desloratadine slow metabolizers. To evaluate the safety and tolerability of desloratadine compared to fexofenadine following single and multiple oral doses administered to desloratadine slow metabolizers.

Condition Intervention Phase
Allergic Rhinitis
Drug: Fexofenadine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine.

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Endpoints will be the AUC and Cmax for desloratadine, 3-OH desloratadine, and fexofenadine. [ Time Frame: Serial, Trough, and Terminal blood samples over 8 days. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Endpoints will include Tmax, elimination half-life (t1/2), and accumulation index, as the data permit. [ Time Frame: Serial, Trough, and Terminal blood samples over 8 days. ] [ Designated as safety issue: No ]

Enrollment: 220
Study Start Date: February 2003
Study Completion Date: January 2004

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy, adult, non-smoking males and females between 18 and 55 years of age, inclusive; Whites of European or North American heritage and Blacks of African or Caribbean heritage.

Exclusion Criteria:

  • Any past or present clinically relevant abnormality, medical condition, or circumstance making the subject unsuitable for participation in the study.
  • Historical, clinical, or laboratory evidence of liver disease including but not limited to transaminase activity concentrations >2.5 times the upper limit of the reference range.
  • Active peptic ulcer disease or a history of gastrointestinal surgery within the last 6 months.
  • History of cholecystectomy.
  • History of malignancy within the last 5 years (except basal cell carcinoma, which must be in remission for at least 6 months prior to the study.
  • Pregnant or lactating females or females of childbearing potential who are unwilling to use reliable, medically accepted methods of contraception. If subjects who are not sexually active with members of the opposite sex become so during the study, these subjects must agree to use a medically accepted method of contraception.
  • History of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines.
  • Treatment with other antihistamines in the last month before study entry.
  • Use of any prescription or over-the-counter medications or dietary/herbal supplements (with the exception of oral or implanted contraceptives) within 1 week or 5 half-lives, whichever is longer, of the study.
  • History of alcoholism or drug abuse within 12 months of the study.
  • Ingestion of alcohol within 1 week of the first dose of study medication.
  • Ingestion of grapefruit or grapefruit juice within 1 week of the study and a willingness to abstain from the consumption of grapefruit or grapefruit juice for the duration of the study.
  • Participation in any other clinical trial or use of an investigational product within 30 days of entry into the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00636870

United States, New Jersey
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Study Director: Phyllis Diener Sanofi
  More Information

Responsible Party: Study Director, sanofi-aventis
ClinicalTrials.gov Identifier: NCT00636870     History of Changes
Other Study ID Numbers: M016455_4124 
Study First Received: March 10, 2008
Last Updated: January 10, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Rhinitis, Allergic
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Anti-Allergic Agents
Cholinergic Agents
Cholinergic Antagonists
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2016